Recombinant human thrombopoietin in myelosuppressive chemotherapy.

摘要: Recombinant human thrombopoietin (rhTPO) is a full-length glycosylated molecule that has been under evaluation in the setting of chemotherapy-induced myelosuppression. It shown to be potent stimulator platelet production cancer patients when administered prior chemotherapy. The peak response single dose rhTPO observed around day 12, and accompanied by significant increase number mature megakaryocytes bone marrow. Consistent with this biologic effect, postchemotherapy effective attenuating severe thrombocytopenia induced carboplatin, which produces late nadir. Early clinical experience regimen an early nadir, however, such as AI (doxorubicin [Adriamycin] ifosfamide [Ifex]), suggests administration both following chemotherapy might important reduce severity. Treatment these trials well tolerated favorable safety profile. Randomized have initiated determine further importance schedule prevention treatment patients.